TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02043145

Intervention type: BIOLOGICAL
Intervention: botulinum toxin Type A
Description: Botulinum toxin Type A (BOTOX®) as prescribed according to standard of care in clinical practice.

Intervention type: BIOLOGICAL
Intervention: botulinum toxin Type A
Description: Botulinum toxin Type A (BOTOX®) as prescribed according to standard of care in clinical practice.

Intervention type: BIOLOGICAL
Intervention: botulinum toxin Type A
Description: Botulinum toxin Type A (BOTOX®) as prescribed according to standard of care in clinical practice.
Study: NCT01720303

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: repaglinide
Description: 2 mg (tablets) before each main meal

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: isophane human insulin
Description: Injection s.c. (under the skin) at bedtime

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: insulin
Description: Injection s.c. (under the skin) twice daily
Study: NCT01055613

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Vistakon Investigational Multi-Purpose Solution I
Description: Multi-purpose contact lens care solution.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: ReNu MultiPlus Multi-Purpose Solution
Description: Multi-purpose contact lens care solution
Study: NCT04379453

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Robot Assisted Percutaneous Cardiovascular Intervention
Description: Robot Assisted Percutaneous Cardiovascular Intervention
Study: NCT03463837

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Treatment with JUUL 5%, Virginia Tobacco
Description: JUUL 5%, ENDS for 5-days in confinement

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Treatment with JUUL 5%, Cool Mint, ENDS
Description: JUUL 5%, ENDS for 5-days in confinement

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Treatment with JUUL 5%, Mango, ENDS
Description: JUUL 5%, ENDS for 5-days in confinement

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: JUUL 5%, Creme Bruele, ENDS
Description: JUUL 5%, ENDS for 5-days in confinement

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Combustible cigarette
Description: Exclusive use of combustible cigarette for 5 days in confinement.

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Smoking Cessation
Description: No smoking for 5-days in confinement.
Study: NCT00755807

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Duloxetine Hydrochloride (HCI)
Description: Participants received 30 mg duloxetine (po, QD) for 1 week followed by 5 weeks at 60 mg in the acute placebo-controlled period. If the participant completes the double-blind portion of the trial, the participant will be offered the option to participate in the open-label extension period (given 60, 90, or 120 mg QD for 12 weeks).

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Participants received placebo oral (po), once daily (QD) for 6 weeks (acute phase). If the participant completes the 6-week double-blind portion of the trial, the participant will be offered the option to participate in the open-label extension period (given 60, 90, or 120 milligrams \[mg\] QD for 12 weeks).
Study: NCT00736112

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Food Allergy Testing
Description: Food Allergy Diagnosis - blood drawn for food allergy testing at the time of surgery (bilateral myringotomy with tympanostomy tubes +/- adenoidectomy)
Study: NCT02872675

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: HOST-DM059
Description: Experimental Supplement: HOST-DM059.~Participants will be asked to orally consume one powdered sachet each day, at the same time in the morning, reconstituted in tea/coffee/fruit juice, or sprinkled over cereal etc. Whichever method of consumption is chosen, this must be kept consistent across both supplementation phases.

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Maltodextrin
Description: Placebo Comparator: Maltodextrin.
Study: NCT03062813

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tacrolimus &entecavir
Description: HBV-GN patients with nephrotic syndrome were randomly givenTacrolimus (0.05-0.1 mg/kg/day) combined with entecavir. Tacrolimus was divided into two daily doses at 12-hour intervals. Subsequent doses were adjusted to achieve a whole blood 12-hour trough level between 5 and 10 ng/ml.All patients will receive entecavir antiviral therapy(0.5mg/d), entecavir was taken once a day. All of HBV-GN patients were followed up to 25week.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: placebo & entecavir
Description: HBV-GN patients with nephrotic syndrome were randomly givenTacrolimus placebo (0.05-0.1 mg/kg/day) combined with entecavir.Tacrolimus placebo was divided into two daily doses at 12-hour intervals. All patients will receive entecavir antiviral therapy(0.5mg/d), entecavir was taken once a day. All of HBV-GN patients were followed up to 25week.
Study: NCT03268213

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Fecal Microbial Transplantation
Description: Fecal microbial transplant is offered as treatment option to eligible patients. Donors selected by the patients will be screened by questionnaire and by blood and stool tests for potential transmissible pathogens.~The stool filtrate will be administered in the ileum and/or cecum via colonoscopy
Study: NCT03752151

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: MARVEL 2 Algorithm Monitor Mode then Adaptive Mode
Description: Software download into implanted Micra device and programmed to MARVEL 2 Monitor Mode then MARVEL 2 Adaptive Mode
Study: NCT00998881

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Teneligliptin 20 mg

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT03803748

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Eyestil Plus®
Description: • To demonstrate the non-inferiority of Eyestil Plus® compared to Vismed Multi® in terms of clinical performance as detected by a reduction of keratitis lesions objectified by staining tests after 1 month of treatment, in patients with moderate to severe dry eye syndrome with keratoconjunctivitis
Study: NCT02292329

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Acai puree, frozen blended it with banana
Description: 150g of acai fruit, frozen blended it with banana.

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Control Macronutrient matched
Description: Macronutrient matched control in water and also prepared with banana.
Study: NCT00586222

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Omega-3 Fatty Acid
Description: 600 mg of eicosapentaenoic acid, 340 g of docosahexanoic acid, and 96 mg gama-linoleic acid for 12 weeks.
Study: NCT02992301

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Alirocumab
Description: Injectable prescription medicine called a PCSK9 inhibitor.
Study: NCT04117399

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Pulmonary rehabilitation
Description: The experimental group receives inspiratory muscle training and aerobic exercise. The Active Comparator group received only aerobic exercise group received only aerobic exercise.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pulmonary rehabilitation
Description: The experimental group receives inspiratory muscle training and aerobic exercise. The Active Comparator group received only aerobic exercise group received only aerobic exercise.
Study: NCT02253641

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Standard Weight Loss Intervention
Description: 14-session/6-month standard behavioral weight loss intervention

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Stress-Focused Weight Loss Intervention
Description: 14-session/6-month tailored behavioral weight loss intervention
Study: NCT04447534

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chloroquine or hydroxychloroquine
Description: Chloroquine or hydroxychloroquine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chloroquine or hydroxychloroquine
Description: Chloroquine or hydroxychloroquine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: zinc
Description: Zinc tablets
Study: NCT06376838

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: DLMR01
Description: Experimental and Acitve Comparator are applied 1 time to each of crow's feet on both sides of the subject.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Rejuran
Description: Experimental and Acitve Comparator are applied 1 time to each of crow's feet on both sides of the subject.
Study: NCT04265898

Intervention type: DEVICE
Intervention: The Digital Virginia Tech Carilion Cognitive Examination
Description: Completion of a newly developed digital cognitive screen

Intervention type: DEVICE
Intervention: The Digital Virginia Tech Carilion Cognitive Examination
Description: Completion of a newly developed digital cognitive screen
Study: NCT02186457

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Polymyxin B in Normal Saline
Description: Antibiotic irrigation via peritoneal lavage
Study: NCT00393029

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: aldesleukin
Description: 720,000 IU/kg intravenously over 15 minutes every 8 hours for up to 5 days

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: aldesleukin
Description: 720,000 IU/kg intravenously over 15 minutes every 8 hours for up to 5 days

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: filgrastim
Description: Beginning on day 1 or 2, administered subcutaneously at a dose of 5 mcg/kg/day (not to exceed 300 mcg/day); continue daily until neutrophil count \> 1.0 x 10\^9/L x 3 days or \> 5.0 x 10\^9/L.
Study: NCT02186457

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo: Normal Saline
Description: Placebo irrigation via peritoneal lavage
Study: NCT01522443

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cabozantinib
Description: Tablets taken orally once daily.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: mitoxantrone
Description: Given by IV once every 3 weeks.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: prednisone
Description: Taken twice a day orally by mouth. Commercially-obtained prednisone tablets will be over-encapsulated in order to blind identity.
Study: NCT00569621

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: physiological saline
Description: intravenous administration
Study: NCT03627507

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Hepa-B
Description: Incepta will manufacture a locally produced Hepatitis B vaccine named 'Hepa- B' which contain recombinant Hepatitis B surface antigen obtaine. This bulk is formulated to prepare finished dosage to manufacture large scale in fully GMP compliant plant. Incepta has conducted preclinical study at Bioneed, India. After successful completion of preclinical study, this non inferiority clinical trial with innovator product is needed for Licensure in Bangladesh.

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Engerix B
Description: .'Engerix B' is a recombinant DNA hepatitis B vaccine. It is sterile suspension of purified surface antigen of hepatitis B virus obtained by culturing genetically yeast cells (Saccharomyces cerevisiae cells), which carry the gene that codes for HBsAg
Study: NCT03098914

Intervention type: OTHER
Intervention: Cohort Study； pathogen； clinical features
Description: Cohort Study； pathogen； clinical features

Intervention type: OTHER
Intervention: Cohort Study； pathogen； clinical features
Description: Cohort Study； pathogen； clinical features

Intervention type: OTHER
Intervention: Cohort Study； pathogen； clinical features
Description: Cohort Study； pathogen； clinical features
Study: NCT01307553

Intervention type: DEVICE
Intervention: Pericardium Covered Stent
Description: Percutaneous implantation of pericardium covered stent
Study: NCT01263314

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MK-8266
Description: Oral capsules, 0.1 mg potency

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MK-8266
Description: Oral capsules, 0.1 mg potency

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MK-8266
Description: Oral capsules, 0.1 mg potency

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MK-8266
Description: Oral capsules, 0.1 mg potency

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MK-8266
Description: Oral capsules, 0.1 mg potency

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MK-8266
Description: Oral capsules, 0.1 mg potency
Study: NCT04146311

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Hypertonic saline
Description: A bolus injection (0.25 ml) of hypertonic saline (5%) into the left infrapatellar fat pad.
Study: NCT01263314

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Oral placebo capsules to match MK-8266 capsules

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Oral placebo capsules to match MK-8266 capsules
Study: NCT02752724

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ketamine
Description: Ketamine anesthesia for ECT index course with measurement cerebral metabolic regional oximetry, EEG seizure quality, cognitive scoring and serum metabolites.
Study: NCT04146311

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: isotonic saline
Description: A bolus injection (0.25 ml) of isotonic saline (5%) into the left infrapatellar fat pad.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Motor training
Description: All the subjects recruited need to have a short-term motor task training at home. 30 times a session, totally 2 sessions a day for 6 days

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Motor training
Description: All the subjects recruited need to have a short-term motor task training at home. 30 times a session, totally 2 sessions a day for 6 days

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Motor training
Description: All the subjects recruited need to have a short-term motor task training at home. 30 times a session, totally 2 sessions a day for 6 days
Study: NCT00586222

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: placebo pill of the same size, color, and shape as the dietary supplement.
Study: NCT04597684

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Cementless Total Knee Arthroplasty
Description: Total Knee Arthroplasty (TKA) with cementless knees
Study: NCT02752724

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Methohexital
Description: Methohexital anesthesia for ECT index course with measurement cerebral metabolic regional oximetry, EEG seizure quality, cognitive scoring and serum metabolites.
Study: NCT00545480

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ibandronate [Bonviva/Boniva]
Description: 150mg po monthly for 12 months (with feedback)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ibandronate [Bonviva/Boniva]
Description: 150mg po monthly for 12 months (without feedback)
Study: NCT04211844

Intervention type: DRUG
Intervention: sofosbuvir plus daclatasvir
Description: 50 patients in the first group will receive 400 mg sofosbuvir plus daclatasvir 60 mg once daily for 12 weeks.
Study: NCT03275766

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: DLPFC facilitatory
Description: 15 Hz stimulation of left dorsolateral prefrontal cortex (DLPFC)(15 sessions/3weeks, 1500 stimuli per session, stimulation intensity 100% of the individual active motor threshold; in total 22500 stimuli

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: SMA inhibitory
Description: 1 Hz stimulation of preSMA/SMA (15 sessions/3weeks, 1500 stimuli per session, stimulation intensity 100% of the individual active motor threshold; in total 22500 stimuli

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: SMA facilitatory
Description: Three pulses of stimulation at 50 Hz of preSMA/SMA, repeated every 200 ms. 2 s trains are repeated every 10 s for a total of 190 s (600 pulses, 200 seconds). intensity 80% of individual active motor threshold; in total 9000 stimuli

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: sham TMS
Description: Determination of active motor threshold and subsequent stimulation with the placebo coil, with the same sounds but without effects. 15 sessions in three weeks, duration of 20 mins per session
Study: NCT06156735

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Passive Music Therapy (P)
Description: Music Therapy Intervention

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Active Music Therapy (A)
Description: Music Therapy Intervention

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard Care Control Condition (C)
Description: Without any intervention
Study: NCT04229524

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Fluorescence angiography
Description: After the tube and stomach were made during surgery, the predetermined anastomosis position was marked with sutures in advance according to the doctor's experience, and then 0.04ml / kg indocyanine green injection was injected into the central vein. Next, dynamic observation and recording of the tube-gastric anastomosis area in 136 seconds using a fluorescent imaging system with a fixed focal length till the fluorescence reaching range and intensity. If the average value of the fluorescence value of the anastomosis position is greater than 30, then the anastomosis position may be according to the original plan or moved to the proximal part. If the average fluorescence value of the predetermined anastomosis position is less than 30, the anastomosis must move to proximal part ensure anastomosis with fluorescence value at least\> 30.
Study: NCT03625518

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: prostaglandins E2
Description: insertion of vaginal PGE2 for up to 30 hours, up to two attempts for cervical ripening and induction

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: intracervical balloon catheter combined with pitocin
Description: insertion of Foley catheter intra cervical and inflating the balloon with 50-60 cc of saline, with IV pitocin according to hospital protocol
Study: NCT04149795

Intervention type: DIAGNOSTIC_TEST
Intervention: Online questionnaire
Description: Online questionnaire via SoSciSurvey
Study: NCT04310813

Intervention type: DIAGNOSTIC_TEST
Intervention: Multimodal spectroscopic analysis
Description: During time of bladder or prostate resection, freshly excised cold cup biopsies of both bladder cancer or healthy bladder mucosa were taken and sent for inspection through label-free multimodal fiber optic spectroscopy (MFOS) within 30 minutes
Study: NCT04006314

Intervention type: OTHER
Group type: OTHER
Intervention: Autologous platelet rich plasma and dextrose solution.
Description: Autologous platelet rich plasma are injected into the knee joint and pes anserinus complex.~Dextrose solutions are injected to the genicular nerves.
Study: NCT02923674

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Weight loss
Description: All participants will undergo a dietary WL intervention designed to elicit behavioral changes leading to decreased caloric intake sufficient to yield a \~10% loss of initial body mass. The WL intervention includes nutrition education, state-of-the-art behavioral methods for promoting WL, and strategies that optimize self-regulation.

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Weight loss
Description: All participants will undergo a dietary WL intervention designed to elicit behavioral changes leading to decreased caloric intake sufficient to yield a \~10% loss of initial body mass. The WL intervention includes nutrition education, state-of-the-art behavioral methods for promoting WL, and strategies that optimize self-regulation.

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Weight loss
Description: All participants will undergo a dietary WL intervention designed to elicit behavioral changes leading to decreased caloric intake sufficient to yield a \~10% loss of initial body mass. The WL intervention includes nutrition education, state-of-the-art behavioral methods for promoting WL, and strategies that optimize self-regulation.

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Exercise
Description: Perform structured aerobic exercise (mostly treadmill walking) of moderate-intensity for 4-5 days/week, progressing to a duration of 200 min/week. Participants will attend center-based sessions for at least 3 days/week during the first intensive 6-month phase and at least one day/week during the second 3-month transition phase (months 7-9), with recording of home-based exercise for the other 2-4 days/week.

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Exercise
Description: Perform structured aerobic exercise (mostly treadmill walking) of moderate-intensity for 4-5 days/week, progressing to a duration of 200 min/week. Participants will attend center-based sessions for at least 3 days/week during the first intensive 6-month phase and at least one day/week during the second 3-month transition phase (months 7-9), with recording of home-based exercise for the other 2-4 days/week.

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Sitless
Description: Encouraged and taught to reduce sedentary behavior (SB) during waking hours. The SitLess treatment targets increases in postural shifts and light, spontaneous physical activity (SPA) (MET level \<3).

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Sitless
Description: Encouraged and taught to reduce sedentary behavior (SB) during waking hours. The SitLess treatment targets increases in postural shifts and light, spontaneous physical activity (SPA) (MET level \<3).
Study: NCT04567914

Intervention type: DIAGNOSTIC_TEST
Intervention: Bilaterally abdominal muscle thickness with ultrasonography
Description: AIS group was evaluated for localization of curvature and degree of curvature. Ultrasonographic measurements were performed of bilaterally abdominal muscle thickness in the supine and standing positions in both groups. Spirometry evaluation was performed in both groups

Intervention type: DIAGNOSTIC_TEST
Intervention: Bilaterally abdominal muscle thickness with ultrasonography
Description: AIS group was evaluated for localization of curvature and degree of curvature. Ultrasonographic measurements were performed of bilaterally abdominal muscle thickness in the supine and standing positions in both groups. Spirometry evaluation was performed in both groups
Study: NCT00197496

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Body weight supported treadmill training
Description: hip fracture patients walk on a treadmill with body weight support